FRANKLIN LAKES, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBI) today announced that the Company has recently responded to the FDA’s request for additional information regarding the Company’s December 2006 510(k) pre-market notification for its collagen scaffold device.
